Inventiva SACA

Inventiva to Participate in Upcoming September Investor Conferences

04 Sep 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

11 Aug 2025 13:00:00 By Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

31 Jul 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva Reports Preliminary 2025 First-Half Financial Information¹

29 Jul 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance

09 Jul 2025 13:05:00 By Nasdaq GlobeNewswire

Inventiva receives $10 million milestone payment from CTTQ

07 Jul 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease

02 Jul 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

10 Jun 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

27 May 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva reports 2025 First Quarter Financial Information¹

22 May 2025 23:30:00 By Nasdaq GlobeNewswire

Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

22 May 2025 23:00:00 By Nasdaq GlobeNewswire

Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux

22 May 2025 05:00:00 By Nasdaq GlobeNewswire

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million

04 May 2025 23:30:00 By Nasdaq GlobeNewswire

Combined General Meeting of May 22, 2025 - Availability of the preparatory documents

30 Apr 2025 13:00:00 By Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025

30 Apr 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor

24 Apr 2025 13:01:28 By Nasdaq GlobeNewswire

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F

15 Apr 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis

01 Apr 2025 14:00:00 By Nasdaq GlobeNewswire

Inventiva reports its 2024 full year results and provides a business update

26 Mar 2025 13:00:00 By Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results

19 Mar 2025 13:00:00 By Nasdaq GlobeNewswire